Campbell Katherine A, Terzic Andre, Nelson Timothy J
Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA.
Regen Med. 2015;10(6):773-83. doi: 10.2217/rme.15.41. Epub 2015 Oct 6.
Induced pluripotent stem (iPS) cell technology offers an unprecedented opportunity to study patient-specific disease. This biotechnology platform enables recapitulation of individualized disease signatures in a dish through differentiation of patient-derived iPS cells. Beyond disease modeling, the in vitro process of differentiation toward genuine patient tissue offers a blueprint to inform disease etiology and molecular pathogenesis. Here, we highlight recent advances in patient-specific cardiac disease modeling and outline the future promise of iPS cell-based disease discovery applications.
诱导多能干细胞（iPS）技术为研究患者特异性疾病提供了前所未有的机遇。这个生物技术平台能够通过患者来源的iPS细胞分化，在培养皿中重现个体化的疾病特征。除了疾病建模，向真正的患者组织分化的体外过程为了解疾病病因和分子发病机制提供了一个蓝图。在这里，我们重点介绍患者特异性心脏病建模的最新进展，并概述基于iPS细胞的疾病发现应用的未来前景。
